DHEA — Research Profile

Yes. DHEA-S blood testing is strongly recommended before starting supplementation. Normal ranges vary by age and sex, and supplementing without knowing your baseline can lead to supraphysiological levels and side effects. A healthcare provider can help interpret results and determine an appropriate dose. Retest DHEA-S levels 4-6 weeks after starting supplementation.

DHEA can be safe for women at appropriate doses (typically 5-25mg daily), which is lower than the standard male dose. Women are more susceptible to androgenic side effects like acne, hair growth, and deepening voice at higher doses because DHEA converts to testosterone. Women should start at 5-10mg and increase only under medical supervision with hormone level monitoring.

DHEA levels begin declining in the late 20s and drop significantly after age 40. Most clinicians recommend considering DHEA supplementation only after age 40, and only if DHEA-S blood levels are confirmed to be below the reference range for your age. Younger adults generally do not benefit from supplementation unless they have adrenal insufficiency or a documented deficiency.

There is no universally best form; it depends on the goal. For local menopausal symptoms (dyspareunia, vaginal dryness), intravaginal prasterone 6.5 mg/day is the form with FDA approval and Phase III support ^[2]. For systemic goals such as bone density, ovarian response, or body composition, oral micronized DHEA (commonly 25-50 mg/day) is what trials used ^[3]. The oral and vaginal routes are not interchangeable, since the vaginal form acts largely locally.

The best-supported use is intravaginal prasterone for postmenopausal dyspareunia and vulvovaginal atrophy, which improved pain and vaginal cell maturation in a Phase III trial ^[2]. Oral DHEA (50 mg/day) increased spine bone mineral density in older women, though not in men ^[3], and DHEA as an IVF adjuvant improved clinical pregnancy rates in poor ovarian responders (OR 1.92) ^[4]. Effects on body composition are modest (about +0.45 kg lean mass and -0.85% fat mass) and of debatable clinical importance ^[12].

No single standard dose exists; it varies by route and goal. Systemic oral trials generally used 25-50 mg/day: 50 mg/day raised spine bone density in older women ^[3] and measurably increased estradiol ^[6]. The menopausal vaginal form is 6.5 mg/day of prasterone ^[2]. Because higher oral doses sharply increase testosterone ^[9], most protocols stay at or below 50 mg/day unless medically supervised.

Timing has not been tested in head-to-head trials. The studies establishing DHEA's effects on bone density and estradiol used once-daily oral dosing without specifying a time of day ^[3][6], and the vaginal prasterone regimen is one insert daily ^[2]. Taking it consistently once per day is what the evidence reflects; no data show that morning versus evening dosing changes outcomes.

Most side effects stem from DHEA converting to sex hormones. Because it raises testosterone ^[8] and estradiol ^[6], commonly reported effects include acne, oily skin, and unwanted hair growth, and in women daily oral use lowers HDL cholesterol (about -5 mg/dL) ^[10]. NCCIH additionally warns of possible liver damage even with short-term use.

Formal drug-interaction trials are limited, but the mechanism creates predictable concerns. DHEA raises estradiol ^[6] and testosterone ^[8], so it can add to estrogen or testosterone therapy and is inadvisable with hormone-sensitive conditions; it also modestly lowers fasting glucose (about -2 mg/dL) ^[11], which could compound diabetes medications. NCCIH notes professional societies recommend against routine DHEA use, so anyone on hormone-related or glucose-lowering drugs should treat it as an active hormone rather than an inert supplement.

DHEA is targeted, not general-purpose. The clearest candidates are postmenopausal women with dyspareunia or vulvovaginal atrophy (vaginal prasterone) ^[2], older women with low bone density (oral DHEA raised spine BMD in women but not men) ^[3], and women with poor ovarian response undergoing IVF, where it improved clinical pregnancy rates ^[4]. It is not supported as an anti-aging or general-wellness supplement, and a multi-society task force advises against routine use.

Onset depends entirely on the target. For menopausal vaginal atrophy, intravaginal prasterone (6.5 mg/day) produced measurable improvements in dyspareunia and vaginal cell maturation over a 12-week trial ^[2]. Systemic effects build more slowly: oral DHEA's rise in estradiol was largest in women supplementing 26 weeks or longer ^[6], and spine bone-density gains in older women accrued over 1-2 years ^[3]. Expect weeks for urogenital and hormonal changes but many months for skeletal outcomes.

Long-term safety is not established. NCCIH states the long-term safety of DHEA is unknown and that even short-term use may cause harm including liver damage, and that a multi-society task force recommends against routine DHEA use. Daily oral use also lowers HDL cholesterol, an effect concentrated in women (about -5 mg/dL) ^[10], on top of androgenic effects from raised sex hormones. It is a hormone precursor, not a benign nutrient, so open-ended daily use without monitoring is not advisable.

There is no established tolerable upper intake level for DHEA because it is a hormone precursor rather than a nutrient. Higher doses do more: a dose-response meta-analysis found testosterone increases roughly three times larger above 50 mg/day (about +58 ng/dL) than at lower doses (about +19 ng/dL) ^[9], which drives androgenic effects such as acne and unwanted hair. NCCIH also flags possible liver damage even with short-term use, so escalating the dose carries real risk.

Genuine supplement co-administration has been tested in at least one setting: a two-year bone-density trial gave 50 mg/day oral DHEA together with vitamin D (16 mcg/day) and calcium (700 mg/day) without reported supplement-supplement problems ^[3]. No specific beneficial DHEA combination is established, and because DHEA is a hormone precursor that raises testosterone and estradiol, stacking it with other hormone-modulating products can compound those effects; Memorial Sloan Kettering specifically warns that DHEA should not be combined with tamoxifen, as it can promote tamoxifen resistance. Treat it as an active hormone when combining, not an inert nutrient.

DHEA is a single defined molecule (prasterone), so the concern is label accuracy rather than a standardized botanical extract. Over-the-counter oral DHEA is not an FDA-standardized product, so favor brands with third-party verification of the stated DHEA content, and do not confuse plain DHEA with 7-keto-DHEA, a metabolite with different effects. Note that the vaginal 6.5 mg prasterone form used for menopausal dyspareunia is a prescription product, not an OTC supplement ^[2].